Cargando…

ISG20 serves as a potential biomarker and drives tumor progression in clear cell renal cell carcinoma

Clear cell renal cell carcinoma (ccRCC) is one of the most common malignancies and lacks reliable biomarkers for diagnosis and prognosis, which results in high incidence and mortality rates of ccRCC. In this study, ISG20, HJURP, and FOXM1 were identified as hub genes via weighted gene co-expression...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Tianbo, Ruan, Hailong, Gao, Su, Liu, Jingchong, Liu, Yuenan, Song, Zhengshuai, Cao, Qi, Wang, Keshan, Bao, Lin, Liu, Di, Tong, Junwei, Shi, Jian, Liang, Huageng, Yang, Hongmei, Chen, Ke, Zhang, Xiaoping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053611/
https://www.ncbi.nlm.nih.gov/pubmed/32003757
http://dx.doi.org/10.18632/aging.102714
_version_ 1783503070231003136
author Xu, Tianbo
Ruan, Hailong
Gao, Su
Liu, Jingchong
Liu, Yuenan
Song, Zhengshuai
Cao, Qi
Wang, Keshan
Bao, Lin
Liu, Di
Tong, Junwei
Shi, Jian
Liang, Huageng
Yang, Hongmei
Chen, Ke
Zhang, Xiaoping
author_facet Xu, Tianbo
Ruan, Hailong
Gao, Su
Liu, Jingchong
Liu, Yuenan
Song, Zhengshuai
Cao, Qi
Wang, Keshan
Bao, Lin
Liu, Di
Tong, Junwei
Shi, Jian
Liang, Huageng
Yang, Hongmei
Chen, Ke
Zhang, Xiaoping
author_sort Xu, Tianbo
collection PubMed
description Clear cell renal cell carcinoma (ccRCC) is one of the most common malignancies and lacks reliable biomarkers for diagnosis and prognosis, which results in high incidence and mortality rates of ccRCC. In this study, ISG20, HJURP, and FOXM1 were identified as hub genes via weighted gene co-expression network analysis (WGCNA) and Cox regression analysis. Samples validation showed that only ISG20 was up-regulated in ccRCC. Therefore, ISG20 was selected for further study. High ISG20 expression was associated with poor overall survival and disease-free survival. Furthermore, the expression of ISG20 could effectively differentiate ccRCC from normal tissues and was positively correlated to clinical stages. Functional experiments proved that knockdown of ISG20 expression could obviously inhibit cell growth, migration, and invasion in ccRCC cells. To find the potential mechanisms of ISG20, gene set enrichment analysis (GSEA) was performed and revealed that high expression of ISG20 was significantly involved in metastasis and cell cycle pathways. In addition, we found that ISG20 could regulate the expression of MMP9 and CCND1. In conclusion, these findings suggested that ISG20 promoted cell proliferation and metastasis via regulating MMP9/CCND1 expression and might serve as a potential biomarker and therapeutic target in ccRCC.
format Online
Article
Text
id pubmed-7053611
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Impact Journals
record_format MEDLINE/PubMed
spelling pubmed-70536112020-03-12 ISG20 serves as a potential biomarker and drives tumor progression in clear cell renal cell carcinoma Xu, Tianbo Ruan, Hailong Gao, Su Liu, Jingchong Liu, Yuenan Song, Zhengshuai Cao, Qi Wang, Keshan Bao, Lin Liu, Di Tong, Junwei Shi, Jian Liang, Huageng Yang, Hongmei Chen, Ke Zhang, Xiaoping Aging (Albany NY) Research Paper Clear cell renal cell carcinoma (ccRCC) is one of the most common malignancies and lacks reliable biomarkers for diagnosis and prognosis, which results in high incidence and mortality rates of ccRCC. In this study, ISG20, HJURP, and FOXM1 were identified as hub genes via weighted gene co-expression network analysis (WGCNA) and Cox regression analysis. Samples validation showed that only ISG20 was up-regulated in ccRCC. Therefore, ISG20 was selected for further study. High ISG20 expression was associated with poor overall survival and disease-free survival. Furthermore, the expression of ISG20 could effectively differentiate ccRCC from normal tissues and was positively correlated to clinical stages. Functional experiments proved that knockdown of ISG20 expression could obviously inhibit cell growth, migration, and invasion in ccRCC cells. To find the potential mechanisms of ISG20, gene set enrichment analysis (GSEA) was performed and revealed that high expression of ISG20 was significantly involved in metastasis and cell cycle pathways. In addition, we found that ISG20 could regulate the expression of MMP9 and CCND1. In conclusion, these findings suggested that ISG20 promoted cell proliferation and metastasis via regulating MMP9/CCND1 expression and might serve as a potential biomarker and therapeutic target in ccRCC. Impact Journals 2020-01-30 /pmc/articles/PMC7053611/ /pubmed/32003757 http://dx.doi.org/10.18632/aging.102714 Text en Copyright © 2020 Xu et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Xu, Tianbo
Ruan, Hailong
Gao, Su
Liu, Jingchong
Liu, Yuenan
Song, Zhengshuai
Cao, Qi
Wang, Keshan
Bao, Lin
Liu, Di
Tong, Junwei
Shi, Jian
Liang, Huageng
Yang, Hongmei
Chen, Ke
Zhang, Xiaoping
ISG20 serves as a potential biomarker and drives tumor progression in clear cell renal cell carcinoma
title ISG20 serves as a potential biomarker and drives tumor progression in clear cell renal cell carcinoma
title_full ISG20 serves as a potential biomarker and drives tumor progression in clear cell renal cell carcinoma
title_fullStr ISG20 serves as a potential biomarker and drives tumor progression in clear cell renal cell carcinoma
title_full_unstemmed ISG20 serves as a potential biomarker and drives tumor progression in clear cell renal cell carcinoma
title_short ISG20 serves as a potential biomarker and drives tumor progression in clear cell renal cell carcinoma
title_sort isg20 serves as a potential biomarker and drives tumor progression in clear cell renal cell carcinoma
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053611/
https://www.ncbi.nlm.nih.gov/pubmed/32003757
http://dx.doi.org/10.18632/aging.102714
work_keys_str_mv AT xutianbo isg20servesasapotentialbiomarkeranddrivestumorprogressioninclearcellrenalcellcarcinoma
AT ruanhailong isg20servesasapotentialbiomarkeranddrivestumorprogressioninclearcellrenalcellcarcinoma
AT gaosu isg20servesasapotentialbiomarkeranddrivestumorprogressioninclearcellrenalcellcarcinoma
AT liujingchong isg20servesasapotentialbiomarkeranddrivestumorprogressioninclearcellrenalcellcarcinoma
AT liuyuenan isg20servesasapotentialbiomarkeranddrivestumorprogressioninclearcellrenalcellcarcinoma
AT songzhengshuai isg20servesasapotentialbiomarkeranddrivestumorprogressioninclearcellrenalcellcarcinoma
AT caoqi isg20servesasapotentialbiomarkeranddrivestumorprogressioninclearcellrenalcellcarcinoma
AT wangkeshan isg20servesasapotentialbiomarkeranddrivestumorprogressioninclearcellrenalcellcarcinoma
AT baolin isg20servesasapotentialbiomarkeranddrivestumorprogressioninclearcellrenalcellcarcinoma
AT liudi isg20servesasapotentialbiomarkeranddrivestumorprogressioninclearcellrenalcellcarcinoma
AT tongjunwei isg20servesasapotentialbiomarkeranddrivestumorprogressioninclearcellrenalcellcarcinoma
AT shijian isg20servesasapotentialbiomarkeranddrivestumorprogressioninclearcellrenalcellcarcinoma
AT lianghuageng isg20servesasapotentialbiomarkeranddrivestumorprogressioninclearcellrenalcellcarcinoma
AT yanghongmei isg20servesasapotentialbiomarkeranddrivestumorprogressioninclearcellrenalcellcarcinoma
AT chenke isg20servesasapotentialbiomarkeranddrivestumorprogressioninclearcellrenalcellcarcinoma
AT zhangxiaoping isg20servesasapotentialbiomarkeranddrivestumorprogressioninclearcellrenalcellcarcinoma